Scott Lee
Gastroenterology · Seattle, WANPI 1316022122
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $175,213 of the $219,797 with a category attached, or 79.7%. 18 manufacturers reported payments, led by Johnson & Johnson at 30.1% of the total. Among gastroenterology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 461 payments — averaging $476.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$66K
- E.r. Squibb & Sons, L.L.C.$26K
- Eli Lilly$23K
- Pfizer$14K
- AbbVie$11K
- Takeda Pharmaceuticals U.S.A., Inc.$11K
- plus $69K from 12 others
Across 279 payments — averaging $12,373 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$991K
- AbbVie$985K
- Janssen Research & Development, LLC$593K
- Bristol Myers Squibb$300K
- Takeda Pharmaceuticals U.S.A., Inc.$216K
- UCB SA$131K
- plus $236K from 8 others
What the payments were for
- Consulting fees$175,21380%
- Speaking & faculty fees$12,2006%
- Travel & lodging$20,1479%
- Food & beverage$12,2376%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 263 | $66,131 |
| E.r. Squibb & Sons, L.L.C. | 12 | $25,595 |
| Eli Lilly | 45 | $22,637 |
| Pfizer | 11 | $13,728 |
| AbbVie | 38 | $11,441 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $11,186 |
| UCB, Inc. | 8 | $11,131 |
| Janssen Scientific Affairs, LLC | 7 | $11,017 |
| Merck | 14 | $9,814 |
| Lilly USA, LLC | 4 | $9,714 |
| Boehringer Ingelheim | 8 | $9,370 |
| Bristol Myers Squibb | 18 | $8,642 |
| Celltrion USA Inc. | 5 | $7,142 |
| Samsung Bioepis Co., Ltd. | 2 | $1,100 |
| UCB SA | 1 | $800 |
| Celltrion, Inc. | 1 | $150 |
| Medtronic | 1 | $140 |
| Boston Scientific | 1 | $59 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$219,797 in reported general payments places this provider in the 95th percentile of 447 gastroenterology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 104 | $2,855,313 |
| Humira(Cf) PenAdalimumab | 28 | $373,950 |
| RinvoqUpadacitinib | 34 | $296,688 |
| Yusimry(Cf) PenAdalimumab-Aqvh | 13 | $13,009 |
| Mesalamine | 13 | $10,608 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 41 | $1,967 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 27 | $1,767 |
| Lactated RingersRinger's Solution,lactated | 29 | $1,528 |
| Colestipol Hcl | 12 | $1,317 |
| Omeprazole | 25 | $739 |
| MethotrexateMethotrexate Sodium | 33 | $702 |
| Pantoprazole Sodium | 26 | $696 |
| Dicyclomine Hcl | 11 | $483 |
| Folic Acid | 18 | $296 |
| Cyanocobalamin InjectionCyanocobalamin (Vitamin B-12) | 11 | $249 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $66,131 | $2,855,313104 claims |
| AbbVieRinvoq | $11,441 | $296,68834 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 447 gastroenterology providers in Washington.
Other gastroenterology in Seattle
- Kris KowdleySeattle$1.4M
- Alyssa ChoiSeattle$102K
- Andrew RossSeattle$99K
- Shayan IraniSeattle$57K
- Laurens JanssensSeattle$56K
- George McDonaldSeattle$53K
- Adam TempletonSeattle$49K
- Sravanthi ParasaSeattle$47K
- Liam HilsonSeattle$37K
- Rotonya CarrSeattle$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.